审核状态: Project audit state: |
通过审核 Successful |
注册号: Registration number: |
ChiCTR-TRC-13004097 |
最近更新时间: Date of Last Refreshed on: |
2017/4/11 17:04:04 |
注册号状态: |
预注册 |
Registration Status: |
Prospective registration |
填写语言: |
中文和英文 |
Language: |
Chinese And English |
注册题目: |
左甲状腺素干预对甲状腺功能正常且TPOAb阳性不孕女性IVF-ET妊娠结局的影响 |
Public title: |
Effect of Euthyrox intervention on In vitro fertilization outcomes among euthyroid women with TPOAb |
注册题目简写: |
|
Public title acronym: |
|
研究课题的正式科学名称: |
左甲状腺素干预对甲状腺功能正常且TPOAb阳性不孕女性IVF-ET结局的影响----开放随机对照研究 |
Scientific title: |
Effect of Euthyrox Intervention on In Vitro Fertilization Outcomes among Euthyroid Women with TPOAb----a Randomized Open Labeled Trial |
研究课题的正式科学名称简写: |
|
Scientific title acronym: |
|
研究课题代号(代码): Study subject ID: |
|
在其它机构的注册号: Secondary ID: |
申请注册联系人: |
王海宁 |
研究负责人: |
洪天配,乔杰 |
Applicant: |
Wang Haining |
Study leader: |
Hong Tianpei, Qiao Jie |
申请注册联系人电话: Applicant telephone: |
+86 18211087263 |
研究负责人电话: Study leader's telephone: |
+86 15611908212, 15611908108 |
申请注册联系人传真 : Applicant Fax: |
+86 10-82266776 |
研究负责人传真: Study leader's fax: |
+86 10-82265515 |
申请注册联系人电子邮件: Applicant E-mail: |
hainingmail@bjmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
TPHO66@bjmu.edu.cn |
申请单位网址(自愿提供): Applicant website(voluntary supply): |
www.bysy.edu.cn |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
申请注册联系人通讯地址: |
北京市花园北路49号,北京大学第三医院内分泌科 |
研究负责人通讯地址: |
北京市花园北路49号,北京大学第三医院 |
Applicant address: |
49 Huanyuanbei Road, Beijing, China |
Study leader's address: |
49 Huanyuanbei Road, Beijing, China |
申请注册联系人邮政编码: Applicant postcode: |
100191 |
研究负责人邮政编码: Study leader's postcode: |
100191 |
申请人所在单位: |
北京大学第三医院 |
||
Applicant's institution: |
Peking Univeristy, Third Hospital |
是否获伦理委员会批准: |
是 |
||
Approved by ethic committee: |
Yes |
||
伦理委员会批件文号: Approved No. of ethic committee: |
2012-s2000 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
批准本研究的伦理委员会名称: |
北京大学第三医院生殖医学伦理委员会 |
||
Name of the ethic committee: |
Ethical Committee of Reproductive Medicine, Peking University, Third Hospital |
||
伦理委员会批准日期: Date of approved by ethic committee: |
2012-03-07 | ||
国家FDA批准文号: Approved No. of SFDA: |
国家FDA批准附件: Approved file of SFDA: |
|
|
国家FDA批准日期: Date of approved by SFDA: |
研究实施负责(组长)单位: |
北京大学第三医院 内分泌科 |
||||||||||||||||||||||
Primary sponsor: |
Endocrinological department, Peking University Third Hospital |
||||||||||||||||||||||
研究实施负责(组长)单位地址: |
北京市花园北路49号,北京大学第三医院 内分泌科 |
||||||||||||||||||||||
Primary sponsor's address: |
49 Huanyuanbei Road, Beijing, China |
||||||||||||||||||||||
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
经费或物资来源: |
自筹 |
||||||||||||||||||||||
Source(s) of funding: |
Investigator initiated study |
||||||||||||||||||||||
研究疾病: |
自身免疫性甲状腺炎 |
||||||||||||||||||||||
Target disease: |
autoimmune thyroiditis |
||||||||||||||||||||||
研究疾病代码: |
|
||||||||||||||||||||||
Target disease code: |
|
||||||||||||||||||||||
研究类型: |
干预性研究 |
||||||||||||||||||||||
Study type: |
Interventional study |
||||||||||||||||||||||
研究所处阶段: |
其它 | ||||||||||||||||||||||
Study phase: |
N/A |
||||||||||||||||||||||
研究目的: |
明确左旋甲状腺素(LT4)干预是否能改善甲状腺功能正常且TPOAb阳性(或称自身免疫性甲状腺疾病TAI)的女性试管婴儿(IVF)妊娠结局。 |
||||||||||||||||||||||
Objectives of Study: |
To clearify the effect of levothyroxin intervention on In vitro fertilization outcomes among euthyroid women with TPOAb |
||||||||||||||||||||||
研究设计: |
随机平行对照 |
||||||||||||||||||||||
Study design: |
Parallel |
||||||||||||||||||||||
纳入标准: |
1. 年龄≥23岁且≤40岁 2. TPOAb阳性 3. 甲状腺功能正常 4. 初次或第二次IVF 5. 新鲜周期 |
||||||||||||||||||||||
Inclusion criteria |
1. To be aged from 23 to 40 year; 2. TPOAb positive; 3. Euthyroid function; 4. First or second IVF circle; 5. Fresh cycle. |
||||||||||||||||||||||
排除标准: |
1. 原有甲状腺疾病(功能异常、放射碘治疗后或者甲状腺肿瘤) 2. 习惯性流产 3. 卵巢早衰(卵泡期FSH≥20miu/L) 4. 患有其它内分泌系统疾病(包括下丘脑、垂体、肾上腺疾病、糖尿病) 5. 肝脏疾病的证据:谷丙转氨酶、谷草转氨酶≥3倍正常上限 6. 肾功能衰竭证据:血清肌酐>130umol/L 7. 心功能不全、严重心律失常、心肌梗死、稳定或者不稳定心绞痛 8. 严重影响病人判断力疾病:精神异常。 |
||||||||||||||||||||||
Exclusion criteria: |
1. History of thyroid disease (hyper orhypo thyroid dysfunction, post radio-iodine therapy, or thyroid tumor); 2. Recurrent Miscarriage; 3. Premature ovary failure; 4. Other endocrinology glands disorder; 5. Liver dysfunction (ALT or AST >=3 times of the normal upper limit); 6. Renal failure: CCr >=130 umol/L; 7. Heart failure, Arrythmia, Myocardial infarctionangina pectoris; 8. Psychiatric disorder. |
||||||||||||||||||||||
研究实施时间: Study execute time: |
从From2012-06-01至To 2018-06-01 |
干预措施: Interventions: |
|
研究实施地点: Countries of recruitment and research settings: |
|
测量指标: Outcomes: |
|
采集人体标本:
Collecting sample(s)
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
性别: |
女性 |
Gender: |
Female |
||||||
随机方法(请说明由何人用什么方法产生随机序列): |
随机表法 |
||||||||
Randomization Procedure (please state who generates the random number sequence and by what method): |
randomization table |
||||||||
UTN(全球唯一识别码): |
盲法: |
非盲法 |
Blinding: |
Non-blinded |
试验完成后的统计结果: |
|
Calculated Results ater
|
|
研究负责(组长)单位: |
|
Organizer institution (leader institution): |
|
资料收集汇总单位: |
6M |
Data collection Institution: |
|
资料管理单位: |
北京大学第三医院 |
Data management Institution: |
Peking University Third Hospital |
资料分析单位: |
北京大学第三医院 |
Data analysis Institution: |
Peking University Third Hospital |